Compounds to inhibit bacterial s-layer protein assembly

Patent metadata

Field	Value
Publication number	US-11377484-B2
Application number	US-201816651713-A
Country	US
Kind code	B2
Filing date	Oct 2, 2018
Priority date	Oct 2, 2017
Publication date	Jul 5, 2022
Grant date	Jul 5, 2022

Abstract

The present invention relates to the field of bacterial Surface (S)-layer proteins, in particular to compounds capable of disrupting the bacterial S-Layer, specifically the S-Layer of Bacillus anthracis . More particularly, the invention provides for single domain antibodies for diagnosis and treatment of infection caused by pathogens with an S-Layer, in particular of Bacillus anthracis infection. The invention relates to S-Layer protein binding agents inhibiting bacterial growth and interrupting S-Layer assembly, useful in the treatment of bacterial infection, more specifically treatment of anthrax disease.

First claim

The invention claimed is:

1. A molecule that specifically binds to a bacterial Surface-layer protein (SLP), wherein the binding of the molecule disintegrates the bacterial surface layer (S-Layer), wherein the molecule is a small molecule, a peptide, a peptidomimetic, an antibody mimetic, an immunoglobulin single variable domain, or an active antibody fragment.

2. The molecule of claim 1 , wherein the bacterial S-Layer is the S-Layer of a pathogen selected from the group consisting of Bacillus species, B. anthracis, B. cereus, B. thuringiensis, Clostridium difficile, Paenibacillus larvae, Caphylobacteri fetus, Campylobacter rectus, Tannerella forsythia, Aeromonas hydrophila, Rickettsia prowazekii, Rickettsia rickettsia, Rickettsia typhi, Serratia marcescens, Aeromonas salmonicida , and Lactobacillus acidophilus.

3. The molecule of claim 1 , wherein the molecule is a Nanobody.

4. The molecule of claim 1 , wherein the bacterial S-Layer protein is the Bacillus anthracis Surface Array protein (Sap).

5. The molecule of claim 4 , wherein the molecule binds a protein domain comprising at least one of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO: 9, and SEQ ID NO:11.

6. The molecule of claim 5 , wherein the protein domain comprises SEQ ID NO:6 and SEQ ID NO:7.

7. The molecule of claim 5 , wherein the molecule binds the epitope of SEQ ID NO:1 comprising the residues 221-222, 271 to 276, residues 316-320, and 328-333.

8. The molecule of claim 1 , wherein the molecule is an immunoglobulin single variable domain or active antibody fragment comprising the amino acid sequence SGSIFR in CDR1 and the amino acid sequence YDYW in CDR3.

9. The molecule of claim 3 , wherein the Nanobody comprises SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, or SEQ ID NO: 25, or a humanized variant thereof.

10. A composition comprising at least one molecule of claim 1 and a pharmaceutically acceptable carrier.

11. A method of treating a subject suffering from B. anthracis infection; the method comprising:
treating the subject with the composition of claim 1 , so as to treat B. anthracis infection in the subject.

Assignees

• Vib Vzw
• Univ Brussel Vrije
• Vrij Univ Brussel

Inventors

• Remaut Han
• Fioravanti Antonella

Classifications

• C07K2317/569

  Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title

• C07K16/1278 Primary

  Bacillus (G) · CPC title

• G01N2333/32

  from Bacillus (G) · CPC title

• A61P31/04 Primary

  Antibacterial agents · CPC title

• A61K2039/505

  comprising antibodies · CPC title